BR112016019176A2 - anticorpos il-21 - Google Patents

anticorpos il-21

Info

Publication number
BR112016019176A2
BR112016019176A2 BR112016019176A BR112016019176A BR112016019176A2 BR 112016019176 A2 BR112016019176 A2 BR 112016019176A2 BR 112016019176 A BR112016019176 A BR 112016019176A BR 112016019176 A BR112016019176 A BR 112016019176A BR 112016019176 A2 BR112016019176 A2 BR 112016019176A2
Authority
BR
Brazil
Prior art keywords
antibodies
methods
compositions
conditions
warranted
Prior art date
Application number
BR112016019176A
Other languages
English (en)
Inventor
Paula Martin Andrea
Natvarlal PATEL Chetankumar
Magrini Fabio
Davies Julian
Mozaffarian Neelufar
Schroeder Oliver
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112016019176A2 publication Critical patent/BR112016019176A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

a presente invenção refere-se a anticorpos humanizados e produzidos por engenharia os quais têm alta afinidade de ligação parae neutralizam a il-21 humana, a métodos de uso dos anticorpos para tratar condições nas quais o antagonismo ou a neutralização dos efeitos da il-21 é garantido, tais como condições autoimunes, acomposições e métodos para produzir de modo recombinante os anticorpos, e a composições farmacêuticas que compreendem os anticorpos.
BR112016019176A 2014-03-21 2015-03-13 anticorpos il-21 BR112016019176A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21
PCT/US2015/020383 WO2015142637A1 (en) 2014-03-21 2015-03-13 Il-21 antibodies

Publications (1)

Publication Number Publication Date
BR112016019176A2 true BR112016019176A2 (pt) 2017-10-10

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016019176A BR112016019176A2 (pt) 2014-03-21 2015-03-13 anticorpos il-21

Country Status (24)

Country Link
US (1) US9394362B2 (pt)
EP (1) EP3119806B1 (pt)
JP (2) JP6053989B2 (pt)
KR (1) KR101859857B1 (pt)
CN (1) CN106061999B (pt)
AP (1) AP2016009450A0 (pt)
AR (1) AR099625A1 (pt)
AU (1) AU2015231777B2 (pt)
BR (1) BR112016019176A2 (pt)
CA (1) CA2939543C (pt)
CL (1) CL2016002281A1 (pt)
EA (1) EA033335B1 (pt)
EC (1) ECSP16075416A (pt)
ES (1) ES2774422T3 (pt)
IL (1) IL246909A0 (pt)
MA (1) MA39342B2 (pt)
MX (1) MX2016012120A (pt)
MY (1) MY177915A (pt)
NZ (1) NZ722518A (pt)
PE (1) PE20161221A1 (pt)
PH (1) PH12016501820A1 (pt)
SG (1) SG11201606705QA (pt)
TW (1) TWI646105B (pt)
WO (1) WO2015142637A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948275C (en) 2014-04-08 2023-10-17 Boston Pharmaceuticals Inc. Binding molecules specific for il-21 and uses thereof
EP3368090A1 (en) * 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3436060A4 (en) * 2016-03-31 2019-12-04 Eli Lilly and Company ANTIBODIES AGAINST IL-21 AND USES THEREOF
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2022536898A (ja) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－１５プロドラッグおよびその使用方法
JP2022545439A (ja) 2019-08-21 2022-10-27 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－２１プロドラッグおよびその使用方法
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2022309238A1 (en) * 2021-07-09 2024-01-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3226365A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2007114861A2 (en) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
RU2504552C2 (ru) * 2007-12-07 2014-01-20 Займодженетикс, Инк. Моноклональные антитела против il-21 человека
HUE036548T2 (hu) * 2007-12-07 2018-08-28 Zymogenetics Inc IL-31-re specifikus humanizált antitest molekulák
JP2014506259A (ja) 2011-01-17 2014-03-13 ノヴォ ノルディスク アー／エス Ｉｌ−２１リガンド
US20140170153A1 (en) * 2011-05-31 2014-06-19 Novo Nordisk A/S Il-21 epitope and il-21 ligands

Also Published As

Publication number Publication date
US9394362B2 (en) 2016-07-19
JP6373944B2 (ja) 2018-08-15
MA39342B2 (fr) 2020-03-31
JP2017093435A (ja) 2017-06-01
PH12016501820A1 (en) 2016-11-07
KR20160124166A (ko) 2016-10-26
CN106061999A (zh) 2016-10-26
MX2016012120A (es) 2016-12-09
MA39342A1 (fr) 2018-03-30
AU2015231777A1 (en) 2016-08-18
ES2774422T3 (es) 2020-07-21
TWI646105B (zh) 2019-01-01
JP2016520088A (ja) 2016-07-11
CL2016002281A1 (es) 2017-06-23
EA201691521A1 (ru) 2017-02-28
TW201623330A (zh) 2016-07-01
ECSP16075416A (es) 2018-05-31
MY177915A (en) 2020-09-25
JP6053989B2 (ja) 2017-01-11
AP2016009450A0 (en) 2016-09-30
EP3119806A1 (en) 2017-01-25
CA2939543C (en) 2018-01-16
KR101859857B1 (ko) 2018-05-18
US20150266954A1 (en) 2015-09-24
EA033335B1 (ru) 2019-09-30
IL246909A0 (en) 2016-09-29
EP3119806A4 (en) 2017-11-01
AR099625A1 (es) 2016-08-03
WO2015142637A1 (en) 2015-09-24
CN106061999B (zh) 2020-07-31
AU2015231777B2 (en) 2017-08-03
EP3119806B1 (en) 2020-01-01
SG11201606705QA (en) 2016-09-29
CA2939543A1 (en) 2015-09-24
NZ722518A (en) 2017-12-22
PE20161221A1 (es) 2016-11-12

Similar Documents

Publication Publication Date Title
BR112016019176A2 (pt) anticorpos il-21
BR112018012164A2 (pt) anticorpos neutralizantes do vírus da imunodeficiência humana
PH12016501644A1 (en) Binding proteins and methods of use thereof
MX2023008693A (es) Polinucleotidos moduladores.
BR112017025529A2 (pt) agentes de ligação ao tigit e usos destes
BR112017010324A2 (pt) método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
BR112017019412A2 (pt) proteínas ligadoras de tslp
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
BR112016003293A2 (pt) anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos
EP3229793A4 (en) Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease
GT201800102A (es) Polipéptidos que inhiben cd4ol
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
MX2016009597A (es) Terapias para el influenzavirus a subtipo h7n9.
BR112018001907A2 (pt) uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica
IN2013MU03118A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements